0 808

Cited 102 times in

Ideal Blood Pressure in Patients With Atrial Fibrillation.

DC Field Value Language
dc.contributor.author김종윤-
dc.contributor.author김태훈-
dc.contributor.author김하얀-
dc.contributor.author박희남-
dc.contributor.author엄재선-
dc.contributor.author유희태-
dc.contributor.author이문형-
dc.contributor.author정보영-
dc.contributor.author김대훈-
dc.date.accessioned2018-10-11T08:57:44Z-
dc.date.available2018-10-11T08:57:44Z-
dc.date.issued2018-
dc.identifier.issn0735-1097-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/163508-
dc.description.abstractBACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for High Blood Pressure in Adults redefined hypertension as systolic blood pressure (BP) ≥130 mm Hg or diastolic BP ≥80 mm Hg. The optimal BP for patients with atrial fibrillation (AF) is uncertain. OBJECTIVES: The goal of this study was to investigate the impacts of the 2017 ACC/AHA guideline and to determine the ideal BP threshold for the management of high BP in patients with AF. METHODS: This study analyzed data for 298,374 Korean adults with oral anticoagulant-naive, nonvalvular AF obtained from the National Health Insurance Service database from 2005 to 2015. RESULTS: According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guideline, 62.2% of the individuals in our sample had hypertension. After applying the 2017 ACC/AHA guideline, 79.4% had hypertension, including 17.2% with newly redefined hypertension (130 to 139/80 to 89 mm Hg). Those with newly redefined hypertension had greater risks of major cardiovascular events (hazard ratio: 1.07; 95% confidence interval: 1.04 to 1.10; p < 0.001), ischemic stroke, intracranial hemorrhage, and heart failure admission, compared with nonhypertensive patients (<130/80 mm Hg). Among patients with AF undergoing hypertension treatment, patients with BP ≥130/80 mm Hg or <120/80 mm Hg were at significantly higher risks of major cardiovascular events than patients with BP of 120 to 129/<80 mm Hg. CONCLUSIONS: Patients with AF and newly redefined hypertension according to the 2017 ACC/AHA guideline were at higher risk of major cardiovascular events, suggesting that the new BP threshold is beneficial for timely diagnosis and intervention. BP of 120 to 129/<80 mm Hg was the optimal BP treatment target for patients with AF undergoing hypertension treatment.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Biomedical-
dc.relation.isPartOfJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleIdeal Blood Pressure in Patients With Atrial Fibrillation.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorDaehoon Kim-
dc.contributor.googleauthorPil-Sung Yang-
dc.contributor.googleauthorTae-Hoon Kim-
dc.contributor.googleauthorEunsun Jang-
dc.contributor.googleauthorHyejung Shin-
dc.contributor.googleauthorHa Yan Kim-
dc.contributor.googleauthorHee Tae Yu-
dc.contributor.googleauthorJae-Sun Uhm-
dc.contributor.googleauthorJong-Youn Kim-
dc.contributor.googleauthorHui-Nam Pak-
dc.contributor.googleauthorMoon-Hyoung Lee-
dc.contributor.googleauthorBoyoung Joung-
dc.contributor.googleauthorGregory Y.H. Lip-
dc.identifier.doi10.1016/j.jacc.2018.05.076-
dc.contributor.localIdA00926-
dc.contributor.localIdA05466-
dc.contributor.localIdA01091-
dc.contributor.localIdA01776-
dc.contributor.localIdA02337-
dc.contributor.localIdA02535-
dc.contributor.localIdA02766-
dc.contributor.localIdA03609-
dc.contributor.localIdA05608-
dc.relation.journalcodeJ01770-
dc.identifier.eissn1558-3597-
dc.identifier.pmid30190001-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0735109718354780-
dc.subject.keywordatrial fibrillation-
dc.subject.keywordcardiovascular outcome-
dc.subject.keywordguideline-
dc.subject.keywordhypertension-
dc.contributor.alternativeNameKim, Jong Youn-
dc.contributor.alternativeNameKim, Tae-Hoon-
dc.contributor.alternativeNameKim, Ha Yan-
dc.contributor.alternativeNamePak, Hui Nam-
dc.contributor.alternativeNameUhm, Jae Sun-
dc.contributor.alternativeNameYu, Hee Tae-
dc.contributor.alternativeNameLee, Moon Hyoung-
dc.contributor.alternativeNameJoung, Bo Young-
dc.contributor.affiliatedAuthorKim, Jong Youn-
dc.contributor.affiliatedAuthorKim, Tae Hoon-
dc.contributor.affiliatedAuthorKim, Ha Yan-
dc.contributor.affiliatedAuthorPak, Hui Nam-
dc.contributor.affiliatedAuthorUhm, Jae Sun-
dc.contributor.affiliatedAuthorYu, Hee Tae-
dc.contributor.affiliatedAuthorLee, Moon Hyoung-
dc.contributor.affiliatedAuthorJoung, Bo Young-
dc.citation.volume72-
dc.citation.number11-
dc.citation.startPage1233-
dc.citation.endPage1245-
dc.identifier.bibliographicCitationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol.72(11) : 1233-1245, 2018-
dc.identifier.rimsid60456-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.